Warning

Laboratorios ERN, S.A. informs that some of the contents of this website are addressed exclusively to healthcare professionals, authorized for prescribing or dispensing of drugs. Specialized knowledge is required for proper interpretation.

_Ernodasa familia

Ernodasa

Streptokinase-Streptodornase

Anti inflammatory enzyme.

Small, easy to swallow capsules.


    Packet with 20 tablets.

    Financed by the S.N.S.

    N.C. 783993.4


    Packet with 40 tablets.

    Financed by the S.N.S.

    N.C. 784017.6


    Packet with 500 tablets.

    N.C. 609073.2

1 capsule every 6 hours for 4 to 6 days.

In acute cases, greater doses can be used as attack therapy.

Maximum therapeutic dose: 2 capsules 4 times a day.

ERNODASA

Composition

Per capsule:
Streptokinase................................10,000 I.U.
Streptodornase................................2,500 I.U.

Excipients: Lactose, magnesium stearate, talc, gelatine, titanium dioxide (E 171), indigotin (E 132) and azorubin (E 122).

Indications:

Treatment of inflammatory processes in which there are collections of blood and/or fibrinous and purulent exudates.

Dosage:

1 capsule every 6 hours for 4 to 6 days.

In acute cases, greater doses can be used as attack therapy.

Maximum therapeutic dose: 2 capsules 4 times a day.

Warning:

"Warnings about excipients"

This medicine contains azorubin as an excipient. It may cause allergic reactions, including asthma especially in patients allergic to acetylsalicylic acid.

Contraindications:

ERNODASA is contraindicated for patients with active hemorrhagic processes, or who have some deficiency in hemostasis.

Relative contraindications:

Patients with a high risk of hemorrhaging (hypertensive, hemiplegic, etc.).

Precautions:

In major surgical operations it is advisable not to begin treatment with ERNODASA until the 7th day following the operation and under suitable supervision.

Interactions:

Prior treatment with anticoagulants is relatively incompatible. The effect of heparin can be blocked with protamine sulphate administered prior to treatment with ERNODASA. Likewise, coumarinic anticoagulants can be neutralized with vitamin K until normalization of the Quick value.

Side effects:

They rarely occur due to the purity of the preparation. Occasionally phenomena of sensitization may appear in individuals with a high percentage of anti-streptokinase and anti-streptodornase antibodies. Treatment consists of suppressing use of ERNODASA and the usual anti-allergic measures.

Intoxication and its treatment:

The active components of ERNODASA are not toxic by themselves. Allergic reactions, although unusual, are treated in the usual way in these cases (antihistamines, corticoids).

Storage conditions:

No special storage conditions are required.

Keep at room temperature.

Prescription and dispensing conditions

By prescription. Financed by S.N.S.

TITULAR
Laboratorios ERN, S.A. C/Perú, 228 - 08020 Barcelona. Spain.

RESPONSIBLE FOR MANUFACTURING:
Laboratorios ERN, S.A. Polígono Industrial Can Salvatella, c/ Gorcs i Lladó, 188 Barberá de Vallés. Barcelona. España